Details

Autor(en) / Beteiligte

• Stinca, Sara
• Barnes, Thomas W
• Vogel, Peter
• Meyers, Wilfried
• Schulte-Pelkum, Johannes
• Filchtinski, Daniel
• Steller, Laura
• Hauser, Thomas
• Manni, Sandro
• Gardiner, David F
• Popik, Sharon
• Roth, Nathan J
• Schuetz, Patrick
• Ito, Etsuro

Titel

Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches

Ist Teil von

• PloS one, 2021-11, Vol.16 (11), p.e0259731-e0259731

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2021

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Plasma-derived intravenous immunoglobulin (IVIg) products contain a dynamic spectrum of immunoglobulin (Ig) G reactivities reflective of the donor population from which they are derived. We sought to model the concentration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG which could be expected in future plasma pool and final-product batches of CSL Behring's immunoglobulin product Privigen. Data was extracted from accessible databases, including the incidence of coronavirus disease 2019 and SARS-CoV-2 vaccination status, antibody titre in convalescent and vaccinated groups and antibody half-life. Together, these parameters were used to create an integrated mathematical model that could be used to predict anti-SARS-CoV-2 antibody levels in future IVIg preparations. We predict that anti-SARS-CoV-2 IgG concentration will peak in batches produced in mid-October 2021, containing levels in the vicinity of 190-fold that of the mean convalescent (unvaccinated) plasma concentration. An elevated concentration (approximately 35-fold convalescent plasma) is anticipated to be retained in batches produced well into 2022. Measurement of several Privigen batches using the Phadia.sup.[TM] EliA.sup.[TM] SARS-CoV-2-Sp1 IgG binding assay confirmed the early phase of this model. The work presented in this paper may have important implications for physicians and patients who use Privigen for indicated diseases.